Eli Lilly offers positive data for Jardiance in treating cardiovascular issues
Eli Lilly (LLY) reported positive data from EMPEROR-Reduced phase III trial. The study aimed to assess the potential of Jardiance in adults with heart failure with reduced ejection fraction, with and without diabetes. The drug candidate was used in conjunction with standard of care and was evaluated against placebo.
The EMPEROR and EMPA-KIDNEY studies are part of the EMPOWER clinical program. The EMPEROR heart failure studies are two phase III, randomized, double-blind trials. The studies evaluated once-daily Jardiance compared with placebo in